Silexion Advances SIL204 Toward Phase 2/3 After Completing Toxicology Studies Silexion Therapeutics (NASDAQ: SLXN) announced that it has successfully completed the required two-species toxicology studies for SIL204, its next-generation RN

(NASDAQ: #SLXN)
#SLXNTheraputics completed toxicology studies for SIL204, confirming no systemic organ toxicity and enabling progression toward Phase 2/3 trials in advanced pancreatic cancer set for Q2 2026.
prismmarketview.com/silexion-adv...

NASDAQ: #SLXN
Silexion Therapeutics announces promising preclinical results for its novel cancer therapy, showing strong anti-tumor activity in early studies. A big step forward in advancing next-gen oncology treatments.
#SLXNTheraputics
prismmarketview.com/silexion-the...